PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results

Hulme, C, Hall, P, Shinkins, B orcid.org/0000-0001-5350-1018 et al. (5 more authors) (2018) PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results. In: Annals of Oncology. ESMO 2018, 19-23 Oct 2018, Munich, Germany. Oxford University Press .

Metadata

Authors/Creators:
Dates:
  • Accepted: 19 October 2018
  • Published (online): 23 October 2018
  • Published: 23 October 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Health Sciences (Leeds) > Academic Unit of Health Economics (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 29 Nov 2018 11:11
Last Modified: 29 Nov 2018 11:11
Published Version: https://academic.oup.com/annonc/article/29/suppl_8...
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/annonc/mdy424.001

Export

Statistics


CORE (COnnecting REpositories)